This inventor holds 1 USPTO granted patent. Top assignee: Deutsches Krebsforschungszentrum Stiftung Des Offentlichen Rechts. Active years: 2002.
Company Filing History:
Years Active: 2002
Title: Marek Los - Innovator in Neuroectodermal Tumor Treatment
Introduction
Marek Los is a prominent inventor based in Heidelberg, Germany. He has made significant contributions to the field of medical research, particularly in the treatment of neuroectodermal tumors. His innovative work has the potential to change the landscape of cancer treatment.
Latest Patents
Marek Los holds a patent for "Betulinic acid and derivatives thereof useful for the treatment of neuroectodermal tumor." This invention is directed towards the use of betulinic acid and its derivatives as potent anti-neuroectodermal agents. The discovery highlights the effectiveness of these compounds in treating neuroectodermal tumors, especially those resistant to conventional chemotherapy. The patent also includes novel compounds and pharmaceutical compositions aimed at improving treatment outcomes for patients.
Career Highlights
Marek Los is affiliated with the Deutsches Krebsforschungszentrum Stiftung Des Öffentlichen Rechts, where he conducts his research. His work has garnered attention for its innovative approach to tackling challenging medical conditions. With a focus on neuroectodermal tumors, he has positioned himself as a key figure in cancer research.
Collaborations
Marek Los has collaborated with notable colleagues, including Klaus Michael Debatin and Simone Fulda. These partnerships have fostered a collaborative environment that enhances the research and development of new treatment methodologies.
Conclusion
Marek Los is a dedicated inventor whose work in the field of neuroectodermal tumor treatment is paving the way for new therapeutic options. His contributions are vital in the ongoing battle against cancer, and his innovative spirit continues to inspire advancements in medical research.